Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lowered its position in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) by 12.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,829 shares of the medical research company’s stock after selling 555 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Exact Sciences were worth $261,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of EXAS. Marshall Wace LLP acquired a new position in shares of Exact Sciences during the second quarter worth $91,558,000. Norges Bank acquired a new position in shares of Exact Sciences during the fourth quarter worth $47,037,000. Capital World Investors grew its stake in shares of Exact Sciences by 17.2% during the first quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock worth $383,652,000 after purchasing an additional 804,159 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Exact Sciences by 4.4% during the third quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock worth $541,823,000 after purchasing an additional 698,740 shares in the last quarter. Finally, Iron Triangle Partners LP purchased a new stake in Exact Sciences in the second quarter valued at $46,950,000. Institutional investors and hedge funds own 89.13% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. TheStreet cut shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Wolfe Research assumed coverage on shares of Exact Sciences in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $95.00 price target for the company. Canaccord Genuity Group reduced their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, Benchmark raised shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target for the company in a research report on Tuesday, January 2nd. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.31.

Get Our Latest Report on EXAS

Insiders Place Their Bets

In other Exact Sciences news, insider Jacob A. Orville sold 1,879 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $56.89, for a total transaction of $106,896.31. Following the transaction, the insider now directly owns 11,754 shares in the company, valued at $668,685.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Jacob A. Orville sold 1,879 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $56.89, for a total value of $106,896.31. Following the sale, the insider now directly owns 11,754 shares in the company, valued at $668,685.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin T. Conroy sold 14,791 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $908,611.13. Following the completion of the sale, the chief executive officer now owns 1,224,357 shares in the company, valued at $75,212,250.51. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,992 shares of company stock worth $4,096,879. 1.30% of the stock is owned by company insiders.

Exact Sciences Trading Up 0.2 %

Shares of Exact Sciences stock opened at $62.10 on Friday. Exact Sciences Co. has a 52-week low of $56.05 and a 52-week high of $100.77. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74. The company’s 50-day simple moving average is $61.75 and its 200-day simple moving average is $65.68. The firm has a market cap of $11.27 billion, a price-to-earnings ratio of -54.47 and a beta of 1.22.

Exact Sciences (NASDAQ:EXASGet Free Report) last issued its earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company had revenue of $646.89 million for the quarter, compared to analyst estimates of $638.83 million. During the same period in the prior year, the business posted ($0.72) earnings per share. The firm’s revenue for the quarter was up 17.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Exact Sciences Co. will post -0.86 earnings per share for the current year.

Exact Sciences Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Articles

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.